Lost earnings among triptan non-responders in the general population of Denmark: a measure of disproportionate migraine-attributed burden and of unrecognised and unmet treatment need
Triptan non-response represents failure of currently available acute treatment options. It is associated with substantial and cumulative lost earnings, highlighting a disproportionate economic burden. These findings underscore the potential economic benefit of recognizing, and rectifying, unmet treatment needs in migraine management.
Authors
- Thomas Folkmann Hansen (ORCID: https://orcid.org/0000-0001-6703-7762)
- Sandra Elkjær Stallknecht (ORCID: https://orcid.org/0000-0002-1721-3665)
- Messoud Ashina (ORCID: https://orcid.org/0000-0003-0951-5804)
- Timothy J. Steiner (ORCID: https://orcid.org/0000-0002-1882-4337)
- Jens Olsen (ORCID: https://orcid.org/0000-0002-6847-1736)
- Ulla Sofie Lønberg (ORCID: https://orcid.org/0000-0002-7577-8648)
- Maria Spanggaard
- Jakob Møller Hansen (ORCID: https://orcid.org/0000-0002-9417-2481)
- Daniel Sloth Hauberg
Institutions
- University of Copenhagen (DK)
- Pfizer (United States) (US)
- Norwegian University of Science and Technology (NO)
- Region Zealand (DK)
- Glostrup Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Pain and Headache Center (US)
- Slagelse Hospital (DK)
- Imperial College London (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1080/13696998.2025.2477342
- Citations
- 4
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.88
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Region Sjælland
- Region Midtjylland
- H. Lundbeck A/S